<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271191</url>
  </required_header>
  <id_info>
    <org_study_id>6-2011-0205</org_study_id>
    <nct_id>NCT02271191</nct_id>
  </id_info>
  <brief_title>Effect of Nicardipine on Renal Function in Deliberate Hypotension</brief_title>
  <official_title>Effect of Nicardipine on Renal Function in Deliberate Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to demonstrate the effect of nicardipine on renal function with
      creatinine clearance, serum cystatin C, urine output and fractional excretion of sodium
      during deliberate hypotension for spine surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To induce deliberate hypotension, pharmacological agents such as inhalation anesthetics,
      calcium channel blockers, beta-adrenergic blockers have been used alone or in combination.
      Nicardipine, classed as a calcium channel blocker, has a peripheral vasodilator effect via
      relaxation of smooth muscle fiber and sympathetic nerve inhibition. Nicardipine expands the
      renal artery and increases glomerular filtration rate. Previous studies reported the renal
      protective effect of nicardipine in cardiac surgery with cardiopulmonary bypass and
      robot-assisted laparoscopic surgery.

      The aim of this study was to demonstrate the effect of nicardipine on renal function with
      creatinine clearance , serum cystatin C, urine output and fractional excretion of sodium
      during deliberate hypotension for spine surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>creatinine clearance</measure>
    <time_frame>after deliberate hypotension, and POD1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum cystatin C</measure>
    <time_frame>before deliberate hypotension, after deliberate hypotension, and POD1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>urine output</measure>
    <time_frame>after deliberate hypotension, and POD1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fractional excretion of sodium</measure>
    <time_frame>before deliberate hypotension, after deliberate hypotension, and POD1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk, injury, failure, loss, and end stage renal disease (RIFLE) criteria</measure>
    <time_frame>before deliberate hypotension, after deliberate hypotension, and POD1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>Nicardipine and Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous nicardipine and remifentanil during deliberate hypotension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous remifentanil during deliberate hypotension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery</description>
    <arm_group_label>Nicardipine and Remifentanil</arm_group_label>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Perdipine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing anterior or posterior spine interbody fusion

        Exclusion Criteria:

          -  Patients with American Society of Anesthesiologists physical status III or IV

          -  Liver dysfunction with aspartate transaminase/alanine transaminase greater than 60/60
             IU/L

          -  Cerebrovascular disease

          -  Anemia of less than hematocrit 24%

          -  Diabetes mellitus

          -  Severe malnutrition

          -  those diuretics or antihypertensive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul Ho Chang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Republic of Korea</affiliation>
  </overall_official>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

